Aura Biosciences (AURA) News Today $8.20 +0.09 (+1.11%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Aura Biosciences, Inc. (NASDAQ:AURA) Shares Purchased by Franklin Resources Inc.Franklin Resources Inc. grew its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 14.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,668,960 shares of the company's stock aftDecember 21 at 4:46 AM | marketbeat.comWellington Management Group LLP Purchases New Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)Wellington Management Group LLP acquired a new stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 116,392 shares of the company's stock, valued at approximately $1,037,000. WelDecember 20 at 3:39 AM | marketbeat.comBuy Recommendation for Aura Biosciences Inc. Based on Promising Clinical Data and Growth ProspectsDecember 17, 2024 | markets.businessinsider.comAura Biosciences, Inc. (NASDAQ:AURA) Shares Sold by Fmr LLCFmr LLC lowered its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 56.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,217 shares of the company's stoDecember 17, 2024 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Sees Large Increase in Short InterestAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 1,030,000 shares, an increase of 8.8% from the November 15th total of 947,100 shares. Based on an average trading volume of 202,000 shares, the short-interest ratio is presently 5.1 days. Approximately 2.4% of the shares of the stock are short sold.December 15, 2024 | marketbeat.comXoma (XOMA) Receives a Hold from TD CowenDecember 2, 2024 | markets.businessinsider.comMuscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGenDecember 2, 2024 | globenewswire.comAura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNovember 26, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Celcuity (CELC)November 19, 2024 | markets.businessinsider.comAura Biosciences, Inc. (NASDAQ:AURA) Insider Janet Jill Hopkins Sells 11,822 SharesNovember 19, 2024 | insidertrades.comHC Wainwright Forecasts Higher Earnings for Aura BiosciencesAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Analysts at HC Wainwright boosted their FY2024 earnings estimates for Aura Biosciences in a report issued on Wednesday, November 13th. HC Wainwright analyst E. White now expects that the company will earn ($1.69) per share for the year, up fromNovember 18, 2024 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 7.6% in OctoberAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,130,000 shares, a growth of 7.6% from the October 15th total of 1,050,000 shares. Based on an average daily trading volume, of 163,000 shares, the days-to-cover ratio is currently 6.9 days. Currently, 2.7% of the company's shares are short sold.November 17, 2024 | marketbeat.comResearch Analysts Set Expectations for AURA FY2024 EarningsAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings estimates for Aura Biosciences in a report issued on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($1.67November 15, 2024 | marketbeat.comAura Biosciences Reports Q3 Financial ResultsNovember 15, 2024 | markets.businessinsider.comPromising Pipeline Developments and Regulatory Milestones Justify Buy Rating for Aura Biosciences IncNovember 15, 2024 | markets.businessinsider.comAura Biosciences (NASDAQ:AURA) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $22.00 price target on shares of Aura Biosciences in a research report on Thursday.November 14, 2024 | marketbeat.comBuy Rating for Aura Biosciences Inc Driven by Promising Clinical Progress and Strategic GrowthNovember 13, 2024 | markets.businessinsider.comAura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Buy" from AnalystsShares of Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) have been assigned an average recommendation of "Buy" from the seven research firms that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy ratiNovember 12, 2024 | marketbeat.comShort Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Decreases By 8.7%Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 1,050,000 shares, a decline of 8.7% from the September 30th total of 1,150,000 shares. Approximately 2.5% of the company's shares are sold short. Based on an average trading volume of 184,900 shares, the days-to-cover ratio is currently 5.7 days.October 30, 2024 | marketbeat.comInsider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 9,200 Shares of StockOctober 30, 2024 | insidertrades.comAura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $98,808.00 in StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Los Pinos Elisabet De sold 9,200 shares of the business's stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00. Following the completion of the sale, the insider now directly owns 320,647 shares in the company, valued at approximately $3,443,748.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.October 29, 2024 | marketbeat.comAura Biosciences (NASDAQ:AURA) Stock Price Down 4.9% After Insider SellingAura Biosciences (NASDAQ:AURA) Shares Down 4.9% Following Insider SellingOctober 22, 2024 | marketbeat.comPromising Phase 1 Results and Strong Safety Profile of Bel-sar Support Buy Rating for Aura Biosciences IncOctober 22, 2024 | markets.businessinsider.comAura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder ValueOctober 22, 2024 | seekingalpha.comAura Biosciences, Inc. (NASDAQ:AURA) CFO Sells $302,325.93 in StockOctober 22, 2024 | insidertrades.comDiet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies RetractedOctober 20, 2024 | msn.comLos Pinos Elisabet De Sells 24,992 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) StockOctober 19, 2024 | insidertrades.comInsider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 24,992 Shares of StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Los Pinos Elisabet De sold 24,992 shares of the firm's stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $12.04, for a total value of $300,903.68. Following the transaction, the insider now owns 329,847 shares in the company, valued at approximately $3,971,357.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.October 18, 2024 | marketbeat.comPromising Phase 1 Trial Results for Aura Biosciences Inc.’s Bel-sar Support Buy RatingOctober 18, 2024 | markets.businessinsider.comTD Cowen Remains a Buy on Aura Biosciences Inc (AURA)October 18, 2024 | markets.businessinsider.comAura Biosciences' Shares Touch 52-Week High on Positive Cancer Drug DataOctober 18, 2024 | marketwatch.comAura Biosciences, Inc. (NASDAQ:AURA) Given Average Recommendation of "Buy" by AnalystsShares of Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are presently covering the company, MarketBeat reports. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy ratinOctober 18, 2024 | marketbeat.comAura Biosciences (NASDAQ:AURA) Hits New 12-Month High After Analyst UpgradeAura Biosciences (NASDAQ:AURA) Hits New 12-Month High After Analyst UpgradeOctober 18, 2024 | marketbeat.comAura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade DiseaseOctober 18, 2024 | benzinga.comPromising Early Clinical Data and Dual Mechanism Boost Aura Biosciences’ Buy RatingOctober 18, 2024 | markets.businessinsider.comMultiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 TrialOctober 17, 2024 | globenewswire.comAura Biosciences, Inc. (NASDAQ:AURA) CTO Sells $72,722.55 in StockOctober 17, 2024 | insidertrades.comMark Plavsic Sells 7,383 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) CTO Mark Plavsic sold 7,383 shares of the stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now directly owns 121,132 shares in the company, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.October 16, 2024 | marketbeat.comShort Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Decreases By 12.2%Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,150,000 shares, a decrease of 12.2% from the September 15th total of 1,310,000 shares. Based on an average daily volume of 160,400 shares, the short-interest ratio is presently 7.2 days. Currently, 2.7% of the company's stock are sold short.October 14, 2024 | marketbeat.comAura Biosciences (NASDAQ:AURA) Stock Quotes, Forecast and News SummaryOctober 13, 2024 | benzinga.com3 Small-Cap Stocks Ready to Deliver Significant GrowthSmall-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout.October 10, 2024 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) is a favorite amongst institutional investors who own 58%October 4, 2024 | finance.yahoo.comRegency Capital Management Inc. DE Sells 97,744 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)Regency Capital Management Inc. DE lowered its holdings in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 12.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 667,311 shares of the company's stock after selliOctober 4, 2024 | marketbeat.comEvercore ISI Remains a Buy on Aura Biosciences Inc (AURA)September 30, 2024 | markets.businessinsider.comEnsign Peak Advisors Inc Sells 105,316 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)Ensign Peak Advisors Inc reduced its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 29.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 251,906 shares of the company's stock after selling 105,316 shSeptember 28, 2024 | marketbeat.comLong Focus Capital Management LLC Has $7.99 Million Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA)Long Focus Capital Management LLC lifted its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 113.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,057,188 shares of the company's stock after purchasinSeptember 27, 2024 | marketbeat.comBuy Rating for Aura Biosciences Inc: Innovative Early Treatment Prospects in Uveal MelanomaSeptember 24, 2024 | markets.businessinsider.comNew Article Competition: Best Value IdeaSeptember 24, 2024 | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Aura Biosciences Inc (AURA)September 24, 2024 | markets.businessinsider.comAura Biosciences (NASDAQ:AURA) Upgraded to "Strong-Buy" by Evercore ISIEvercore ISI raised Aura Biosciences to a "strong-buy" rating in a research report on Monday.September 18, 2024 | marketbeat.com Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. AURA Media Mentions By Week AURA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AURA News Sentiment▼1.660.60▲Average Medical News Sentiment AURA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AURA Articles This Week▼52▲AURA Articles Average Week Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Xencor News Today Evotec News Today Arcutis Biotherapeutics News Today Nurix Therapeutics News Today Arcus Biosciences News Today Kiniksa Pharmaceuticals News Today Immunocore News Today Ocular Therapeutix News Today Mesoblast News Today Intellia Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AURA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AURA Stock Alerts